Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate cancer update: 2007.

Amy M Lin1, Eric J Small

  • 1UCSF Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA. amlin@medicine.ucsf.edu

Current Opinion in Oncology
|April 9, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.

Genome biology·2026
Same author

Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.

Cancer·2025
Same author

A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.

Nature communications·2025
Same author

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer.

Nature genetics·2025
Same author

Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer.

JNCI cancer spectrum·2025
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

This review covers key advances in prostate cancer risk assessment, diagnosis, and treatment. New findings impact Gleason scoring, PSA interpretation, and cardiovascular risks of androgen deprivation therapy.

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer management requires continuous updates on risk assessment, diagnosis, and treatment strategies.
  • Evolving research provides new insights into prognostic factors and therapeutic interventions.

Purpose of the Study:

  • To review significant developments in prostate cancer risk assessment, diagnosis, and treatment over the past year.
  • To highlight advancements relevant to clinical practice for oncologists and urologists.

Main Methods:

  • This is a review article synthesizing recent research findings.
  • Key developments are identified and summarized from the latest scientific literature.

Main Results:

  • Refined prognostic importance of tertiary Gleason 5 pattern and PSA levels with finasteride.

Related Experiment Videos

  • Evidence supports active treatment for elderly men with localized prostate cancer.
  • Adjuvant radiotherapy benefits specific high-risk postprostatectomy patients.
  • Development of a comprehensive nomogram for salvage radiotherapy.
  • Emerging data on cardiovascular risks of androgen deprivation therapy (ADT), even with shorter durations.
  • First prospective trial defining taxane-resistant prostate cancer in advanced disease.

    • Conclusions:

    • Recent findings have significant implications for the diagnosis and management of prostate cancer.
    • These advancements will guide urologists, radiation oncologists, and medical oncologists in patient care.
    • The review emphasizes the dynamic nature of prostate cancer research and its clinical applications.